Compare CHGG & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHGG | VANI |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.4M | 91.9M |
| IPO Year | 2013 | 2014 |
| Metric | CHGG | VANI |
|---|---|---|
| Price | $0.77 | $1.49 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $1.50 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 1.1M | 278.3K |
| Earning Date | 02-09-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $447,733,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.44 | $0.91 |
| 52 Week High | $1.90 | $1.92 |
| Indicator | CHGG | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 34.48 | 63.67 |
| Support Level | $0.75 | $1.23 |
| Resistance Level | $0.99 | $1.57 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 8.67 | 74.93 |
Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Subscription Services, which encompasses Chegg Study Pack, Chegg Study, Chegg Writing, Chegg Math, and Busuu offerings that can be accessed internationally through the company's websites and on mobile devices, and Skills and Other, which encompasses skills, advertising services, print textbooks, and eTextbooks offerings.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.